ANI Pharma (ANIP) Misses Q2 EPS by 1c

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.67, $0.01 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $48.05 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Zurn Water Solutions (ZWS) Reiterated at Buy by Stifel on New Product Development Momentum
• Rithm Capital Corp. (RITM) PT Lowered to $14 at UBS on Higher for Longer Rates